Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.
The chaperome constitutes a broad family of molecular chaperones and co-chaperones that facilitate the folding, refolding, and degradation of the proteome. Heat shock protein 90 (Hsp90) promotes the folding of numerous oncoproteins to aid survival of malignant phenotypes, and small molecule inhibitors of the Hsp90 chaperone complex offer a viable approach to treat certain cancers. One therapeutic attribute of this approach is the selectivity of these molecules to target high affinity oncogenic Hsp90 complexes present in tumor cells, which are absent in nontransformed cells. This selectivity has given rise to the idea that disease may contribute to forming a stress chaperome that is functionally distinct in its ability to interact with small molecule Hsp90 modulators. Consistent with this premise, modulating Hsp90 improves clinically relevant endpoints of diabetic peripheral neuropathy but has little impact in nondiabetic nerve. The concept of targeting the "diabetic chaperome" to treat diabetes and its complications is discussed.
Department of Pharmacology and Toxicology, The University of Kansas, 5064 Malott Hall 1251 Wescoe Hall Dr., Lawrence, KS, 66045, USA. dobrowsky@ku.edu.
Rick T
RT
Dobrowsky
D000818:Animals; D003929:Diabetic Neuropathies / Q000628:therapy*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D018832:Molecular Chaperones / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D020543:Proteome / Q000378:metabolism*
D018841:HSP90 Heat-Shock Proteins; D018832:Molecular Chaperones; D020543:Proteome
Bioenergetics; Heat shock proteins; Inflammation; Molecular chaperones; Neurodegeneration; Oxidative stress